Cook et al., 2015, demonstrated that Luteolin treatment resulted in a reduction in the viability of breast cancer cells, progestin-dependent VEGF secretion from breast cancer cells, and tumor growth in the human breast cancer xenograft model dependent on medroxyprogesterone acetate, synthetic progestin [127]. Here, VEGFA is linked to breast cancer.